Aspo has published its Annual Report 2024
Aspo has published its Annual Report 2024
Aspo Group's Annual Report 2024 has been published on the company's website aspo.com.
The Annual Report 2024 includes the Strategy and Business Review, the Board of Directors' Report, the Corporate Governance Statement and the Financial Statements 2024.
The Board of Directors' Report includes the Sustainability Statement, which is based on the EU Corporate Sustainability Reporting Directive (CSRD). The audit firm Deloitte Oy has assured the Sustainability Statement at a limited assurance level.
The Consolidated Financial Statements are published in accordance with European Single Electronic Format (ESEF) reporting requirements, and it is available separately in XHTML format where the primary statements and the notes to the financial statements have been labelled with XBRL tags.
Aspo has also published a separate Remuneration Report for 2024, which is available on the company's website.
Aspo's Annual Report in its entirety, as well as the ESEF report and the Remuneration Report are attached to this release.
Aspo Plc Rolf Jansson CEO
Further information: Rolf Jansson, CEO, Aspo Plc, tel. +358 400 600 264, rolf.jansson@aspo.com Distribution: Nasdaq Helsinki Key Media www.aspo.com Aspo creates value by owning and developing business operations sustainably and in the long term. Our companies aim to be market leaders in their sectors. They are responsible for their own operations, customer relationships and the development of these aiming to be forerunners in sustainability. Aspo supports its businesses profitability and growth with the right capabilities. Aspo Group has businesses in 17 different countries, and it employs approximately 800 professionals.
Attachments
Aspo-Remuneration-Report-2024
Aspo-Annual-Report-2024
aspooyj-2024-12-31-en
Aspo-Corporate-Governance-Statement-2024
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
18 hours ago
- Business Wire
Archer Completes 55 Mile Flight—Longest Yet For Piloted Midnight Aircraft
SALINAS, Calif.--(BUSINESS WIRE)--Archer Aviation (NYSE: ACHR) today announced that its Midnight aircraft successfully completed its longest piloted flight to date, flying approximately 55 miles in 31 minutes at speeds exceeding 126 mph. The flight took place at Archer's flight test facility in Salinas, California, in front of United Airlines' Chief Financial Officer, Mike Leskinen, who led United Airlines' early investment in Archer. Test flights in the preceding week reached speeds of nearly 150 mph over a variety of patterns. This latest achievement marks another major milestone in Archer's envelope expansion program as the company advances toward FAA certification in the U.S. and near-term commercialization in the UAE. The flight was conducted as a conventional takeoff and landing mission. Four of Archer's test pilots are now regularly conducting test flights in Midnight, underscoring the program's continued progress and maturity. Adam Goldstein, Archer's Founder and CEO, said, 'I was proud to be on the tarmac with the team for this flight. Crossing the 50-mile mark at speed is another clear step toward commercialization that shows the maturity of our program.' Mike Leskinen, Executive Vice President and CFO of United, said: 'I've been a longtime supporter of bringing sustainable forms of aviation to market. Congratulations to the Archer team on achieving this milestone flight—I was impressed by how quiet the aircraft was.' The Experimental Test Pilot for this flight shared: 'Throughout the thirty-minute flight, the aircraft performed consistently, with predictable handling. It was a beautiful day to be behind the controls.' Midnight flight test pilots will continue to expand speed and duration, and test mission profiles that map to early commercial operations. This milestone follows a series of key developments in Archer's commercialization roadmap, including the continuation of its manufacturing ramp throughout the U.S. and the activation of its Launch Edition program in the UAE. About Archer Archer is designing and developing the key enabling technologies and aircraft necessary to power the future of aviation. To learn more, visit Forward-Looking Statements This press release contains forward looking statements regarding Archer's future business plans and goals, including statements regarding Archer's aircraft performance, and Archer's plans to develop, certify, manufacture and commercialize its aircraft. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. The risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed in Archer's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, available at In addition, please note that any forward-looking statements contained herein are based on assumptions that Archer believes to be reasonable as of the date of this press release. Archer undertakes no obligation to update these statements as a result of new information or future events. Source: Archer Aviation Text: ArcherIR
Associated Press
a day ago
- Associated Press
PureTech Health: Notice of Half-Yearly Results
BOSTON--(BUSINESS WIRE)--Aug 18, 2025-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company') plans to announce its half-yearly results for the six months ended June 30, 2025, on Thursday, August 28, 2025. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and a webcast of the presentation will be available on the Company's website at About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on X (formerly Twitter) @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those statements that relate to the timing of the Company's financial reporting and the Company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption 'Risk Factors' in our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. View source version on CONTACT: PureTech Public Relations [email protected] Investor Relations [email protected] KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH FDA CLINICAL TRIALS SOURCE: PureTech Health plc Copyright Business Wire 2025. PUB: 08/18/2025 02:00 AM/DISC: 08/18/2025 01:59 AM
Yahoo
a day ago
- Yahoo
Aspo Plc's Half-year Financial Report, January 1 – June 30, 2025: Continued profit improvement in a challenging market
Aspo Plc Half-year Financial Report August 18, 2025, at 9.00 am EESTAspo Plc's Half-year Financial Report, January 1 – June 30, 2025: Continued profit improvement in a challenging market This is a summary of the Half-year Financial Report January 1 – June 30, 2025 of Aspo Plc. The complete report is attached to this release and available at April–June 2025 Net sales increased to EUR 162.8 (153.5) million Comparable EBITA grew to EUR 9.2 (7.4) million, 5.6% (4.8%) of net sales. The comparable EBITA of ESL Shipping was EUR 5.0 (6.1) million, Telko EUR 4.3 (1.8) million, and Leipurin EUR 1.7 (1.3) million EBITA was EUR 8.9 (6.9) million. EBITA of ESL Shipping was EUR 4.7 (5.9) million, Telko EUR 4.3 (1.7) million, and Leipurin EUR 1.7 (1.0) million Comparable ROE was 16.5% (9.9%) Comparable earnings per share were EUR 0.19 (0.09) Free cash flow was EUR 13.2 (26.4) million driven by investments Aspo repaid the hybrid bond of EUR 30 million and the related interest of EUR 2.6 million in June After the reporting period, on August 15, 2025, Aspo signed an agreement to divest its Leipurin business to Lantmännen at an enterprise value of EUR 63 million. Upon completion, the transaction is estimated to generate a sales gain of approximately EUR 16 million. The closing of the transaction is subject to regulatory approvals and it is expected to be completed in the first quarter of 2026 January–June 2025 Net sales increased to EUR 314.0 (286.2) million Comparable EBITA grew to EUR 18.0 (12.4) million, 5.7% (4.3%) of net sales. The comparable EBITA of ESL Shipping was EUR 9.1 (8.8) million, Telko EUR 8.7 (4.2) million, and Leipurin EUR 3.1 (2.5) million EBITA was EUR 16.6 (3.9) million. EBITA of ESL Shipping was EUR 7.7 (1.0) million, Telko EUR 8.7 (4.1) million, and Leipurin EUR 3.1 (2.1) million Comparable ROE was 14.3% (8.0%) Comparable earnings per share were EUR 0.31 (0.18) Free cash flow was EUR 8.8 (22.9) million driven by investments Figures from the corresponding period in 2024 are presented in for 2025 Aspo Group's comparable EBITA is expected to be EUR 35 - 45 million in 2025 (EUR 29.1 million in 2024). Aspo Group's comparable EBITA expectation includes the comparable EBITA of the whole Group, including Leipurin business. The divestment of Leipurin was announced on August 15, 2025. Assumptions behind the guidance Aspo's operating environment is expected to remain challenging during the second half of the year. Continued geopolitical uncertainty and global trade tensions are expected to have a negative impact on economic growth and global trade. Increased defense and infrastructure spending in Europe may support the economic recovery towards the end of the year. Aspo's profit improvement for the year is expected to come mainly from the profit generation of the Green Coaster vessels, from Telko's and Leipurin's acquisitions completed in 2024, as well as from various intensified profit improvement actions throughout Aspo's businesses. The higher end of the estimated comparable EBITA range may be realized if all the planned profit improvement measures are successful, and there will be a clear economic recovery during the second half of the year. The lower end of the range may be realized if the economic recovery is further delayed, or significant volumes would be lost or margins impacted negatively due to some unforeseen negative events. Continued trade tensions may have an indirect negative impact on the volumes and price levels of Aspo's businesses. Direct impacts are expected to be modest. For ESL Shipping, demand is expected to continue weak during the second half of the year, with fairly low contractual volumes combined with low spot market pricing. Volumes are expected to be soft during the third quarter of 2025 and slowly revive towards the end of the year. For Telko, overall stable market development is expected going forward. After successfully completing three acquisitions in 2024, the focus in 2025 is on integrating the acquired companies and securing organic growth and positive profitability development. Acquisition-related expenses are expected to be at a clearly lower level in 2025 than in 2024. For Leipurin, the market is expected to be stable. There continues to be opportunities for growth in the food industry, where the addressable market for Leipurin is multiple compared to the bakery sector. Leipurin remains in a good position to continue improving its figures 4-6/2025 4-6/2024 1-6/2025 1-6/2024 1-12/2024 Net sales, MEUR 162.8 153.5 314.0 286.2 592.6 EBITA, MEUR 8.9 6.9 16.6 3.9 21.2 Comparable EBITA, MEUR 9.2 7.4 18.0 12.4 29.1 Comparable EBITA, % 5.6 4.8 5.7 4.3 4.9 Profit for the period, MEUR 6.6 3.9 10.4 -2.2 7.3 Comparable profit for the period, MEUR 6.9 4.4 11.9 6.3 15.2 Earnings per share (EPS), EUR 0.18 0.07 0.27 -0.09 0.14 Comparable EPS, EUR 0.19 0.09 0.31 0.18 0.39 Free cash flow, MEUR 13.2 26.4 8.8 22.9 -36.1 Free cash flow per share, EUR 0.4 0.8 0.3 0.7 -1.2 Comparable ROCE, % 8.9 9.4 8.9 8.0 8.1 Return on equity (ROE), % 15.8 8.8 12.6 -2.7 4.4 Comparable ROE, % 16.5 9.9 14.3 8.0 9.2 Invested capital, MEUR 407.8 307.5 403.7 Net debt, MEUR 224.2 119.6 188.0 Net debt / comparable EBITDA, 12 months rolling 3.7 2.0 3.2 Equity per share, EUR 4.05 4.63 5.13 Equity ratio, % 27.6 37.2 36.9 The calculation principles of key figures are included in Aspo's Board of Directors' report for the year 2024. The figures presented in this half-year financial report have been individually rounded or calculated based on exact figures so the figures may not add to rounded totals and may differ from previously published Jansson, CEO of Aspo Group, comments on the second quarter of 2025:Profitability improvement is at the top of Aspo's agenda for the year 2025, taking benefit of the completed acquisitions and capex investments made during previous years. Currently, we do not build our plans on a significant positive impact from a recovery of the economy during the second half of the year 2025. Market uncertainty has increased, shortening customer planning horizons and slowing down industrial activity. With this in mind, we place even further emphasis on executing a wide range of actions to improve profitability across all Aspo's businesses. Despite the challenging market, Aspo continued to grow and improve its profitability during the second quarter of 2025. Aspo's net sales grew by 6.0% compared to the second quarter of 2024 and the comparable EBITA was EUR 9.2 million compared to EUR 7.4 million in the corresponding period in the previous year. I am proud of Aspo team for generating continued profit growth despite the current market circumstances. ESL Shipping's comparable EBITA was EUR 5.0 (6.1) million. ESL Shipping's profitability was negatively impacted by the continued very weak spot market and softer than expected forest industry demand. On the positive side, steel industry activity remained at a healthy level and the project cargo market offered new freight opportunities. ESL Shipping has six new electric hybrid Green Coaster vessels in operation, and the fleet renewal has already considerably improved energy efficiency and competitiveness. Telko's comparable EBITA of EUR 4.3 (1.8) million more than doubled primarily due to the contribution of acquisitions completed in 2024, as well as the absence of M&A costs. Telko has improved its product and service mix leading to growth in sales margin. In July 2025, Telko achieved a Gold Medal in the Ecovadis sustainability rating. Leipurin's comparable EBITA was was record-high at EUR 1.7 (1.3) million. Leipurin's profitability improvement relates specifically to Sweden, including the acquisition made in 2024, organic growth and measures to improve supply chain efficiency. When summing up the first half of year 2025, Aspo achieved net sales growth of 9.7% and the comparable EBITA was EUR 18.0 million compared to EUR 12.4 million in the corresponding period previous year. All businesses improved their profitability with very limited support from the market, showing that company actions have been successful. After the review period, on August 15, 2025, Aspo announced the divestment of Leipurin to Lantmännen. This transaction is estimated to generate a sales gain of approximately EUR 16 million which will strengthen the balance sheet of Aspo and support the compounder strategy of Telko. This is a major step in executing Aspo's vision and the transaction is a result of a very successful transformation of Leipurin during the past couple of years. Instrumental in this transformation were an increased focus on food ingredients, a complete shift from 'East to West', major organic and non-organic growth investments, and company-wide profit improvement efforts. The closing of the transaction is subject to regulatory approvals and it is expected to be completed in the first quarter of 2026. Our short-term focus lies on profitability improvement, benefitting from the Green Coaster investments made, the acquisitions completed during 2024, and the vast array of profitability improvement efforts ongoing across the Group. In the longer term, we continue to make progress in reaching the financial ambition of Aspo as well as our vision, creating two separate companies out of Aspo, namely Aspo Infra (ESL Shipping) and Aspo Compounder (Telko). The divestment of Leipurin is a major step in executing this vision along with Telko's already completed M&A activities and ESL Shipping's significant investments in best-in-class performance and targets Aspo's long-term financial targets are: Minimum increase in net sales: 5–10% a year Comparable EBITA of 8% Return on equity: more than 20% Net debt to comparable EBITDA, rolling 12 months ratio below 3.0 At a business level, ESL Shipping's long-term comparable EBITA target is 14%, Telko's 8% and Leipurin's 5%. In January–June 2025, Aspo's net sales grew by 9.7% to EUR 314.0 (286.2) million. The comparable EBITA rate stood at 5.7% (4.3%). Comparable return on equity was 14.3% (8.0%) and the net debt to comparable EBITDA, rolling 12 months ratio was 3.7 (2.0).Espoo, August 18, 2025Aspo PlcBoard of DirectorsNews conference for analysts, investors and media News conference for analysts, investors and media will be held at Sanomatalo, Flik Studio Eliel, Töölönlahdenkatu 2, Helsinki on August 18, 2025, at 12.00 p.m. The event is also open to private investors, and participants are requested to register beforehand by emailing viestinta@ The half-year financial report will be presented by CEO Rolf Jansson and CFO Erkka Repo. The event will be held in English, and it can also be followed as a live webcast at Questions can be asked through conference call connection and webcast form. In order to receive the phone numbers and a identifier for the conference call, participants are requested to register using this link: A recording of the event will be available later the same day on the company's website For more information, please contact:Rolf Jansson, CEO, Aspo Plc, tel. +358 400 600 264, Distribution:Nasdaq HelsinkiKey Attachment Aspo-Half-year-Financial-Report-Q2-2025Sign in to access your portfolio
